NYSE:KDMN - Kadmon Stock Price, Price Target & More

$4.19 -0.14 (-3.23 %)
(As of 04/19/2018 04:00 PM ET)
Previous Close$4.33
Today's Range$4.16 - $4.32
52-Week Range$2.05 - $5.86
Volume252,830 shs
Average Volume880,613 shs
Market Capitalization$345.24 million
P/E Ratio-2.95
Dividend YieldN/A
Beta3.97

About Kadmon (NYSE:KDMN)

Kadmon logoKadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics within autoimmune and fibrotic, oncology, and genetic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including those indicated for the management of rare diseases. Its lead product candidates include KD025, a rho-associated coiled-coil kinase2 inhibitor, which is in Phase II clinical studies for the treatment of autoimmune, fibrotic, and neurodegenerative diseases; Tesevatinib, an oral tyrosine kinase inhibitor that is in Phase II clinical studies for use in the treatment of non-small cell lung cancer and glioblastoma, as well as for treating autosomal dominant polycystic kidney disease; and KD034 that is used for the treatment of Wilson's disease, a genetic liver disease. Kadmon Holdings, Inc. has a strategic collaborations and license agreements with Symphony Evolution, Inc.; Nano Terra, Inc.; Dyax Corp.; Chiromics, LLC; VIVUS, Inc.; MeiraGTx Limited; AbbVie Inc.; Zydus Pharmaceuticals USA, Inc.; Jinghua Pharmaceutical Group Co., Ltd.; and Camber Pharmaceuticals, Inc. The company is headquartered in New York, New York.

Receive KDMN News and Ratings via Email

Sign-up to receive the latest news and ratings for KDMN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:KDMN
CUSIPN/A
Phone212-308-6000

Debt

Debt-to-Equity RatioN/A
Current Ratio1.24%
Quick Ratio1.23%

Price-To-Earnings

Trailing P/E Ratio-2.95
Forward P/E Ratio-3.77
P/E GrowthN/A

Sales & Book Value

Annual Sales$12.26 million
Price / Sales26.88
Cash FlowN/A
Price / CashN/A
Book Value($0.49) per share
Price / Book-8.55

Profitability

EPS (Most Recent Fiscal Year)($1.42)
Net Income$-79,770,000.00
Net Margins-650.47%
Return on EquityN/A
Return on Assets-110.26%

Miscellaneous

Employees101
Outstanding Shares78,640,000

How to Become a New Pot Stock Millionaire

Kadmon (NYSE:KDMN) Frequently Asked Questions

What is Kadmon's stock symbol?

Kadmon trades on the New York Stock Exchange (NYSE) under the ticker symbol "KDMN."

How were Kadmon's earnings last quarter?

Kadmon Co. (NYSE:KDMN) posted its quarterly earnings results on Tuesday, March, 6th. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.12. The business earned $1.50 million during the quarter, compared to the consensus estimate of $3.07 million. The company's revenue for the quarter was down 65.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.50) EPS. View Kadmon's Earnings History.

What price target have analysts set for KDMN?

4 analysts have issued 1-year price objectives for Kadmon's shares. Their forecasts range from $3.00 to $25.00. On average, they anticipate Kadmon's stock price to reach $13.25 in the next twelve months. View Analyst Ratings for Kadmon.

Who are some of Kadmon's key competitors?

Who are Kadmon's key executives?

Kadmon's management team includes the folowing people:
  • Dr. Harlan W. Waksal, Pres, CEO & Director (Age 65)
  • Mr. Konstantin Poukalov, Exec. VP & CFO (Age 34)
  • Mr. Steven N. Gordon, Chief Admin., Compliance & Legal Officer, Exec. VP & Gen. Counsel (Age 50)
  • Mr. Charles Darder, Principal Accounting Officer & Controller
  • Dr. John L. Ryan M.D., Ph.D., Chief Medical Officer and Exec. VP (Age 75)

When did Kadmon IPO?

(KDMN) raised $101 million in an IPO on Wednesday, July 27th 2016. The company issued 5,600,000 shares at a price of $16.00-$20.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.

Has Kadmon been receiving favorable news coverage?

Media stories about KDMN stock have been trending somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Kadmon earned a media sentiment score of 0.03 on Accern's scale. They also assigned news stories about the company an impact score of 45.42 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of Kadmon?

Shares of KDMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kadmon's stock price today?

One share of KDMN stock can currently be purchased for approximately $4.19.

How big of a company is Kadmon?

Kadmon has a market capitalization of $345.24 million and generates $12.26 million in revenue each year. The company earns $-79,770,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis. Kadmon employs 101 workers across the globe.

How can I contact Kadmon?

Kadmon's mailing address is 450 East 29th Street, New York NY, 10016. The company can be reached via phone at 212-308-6000 or via email at [email protected]


MarketBeat Community Rating for Kadmon (KDMN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  128 (Vote Outperform)
Underperform Votes:  99 (Vote Underperform)
Total Votes:  227
MarketBeat's community ratings are surveys of what our community members think about Kadmon and other stocks. Vote "Outperform" if you believe KDMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KDMN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Kadmon (NYSE:KDMN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Kadmon in the last 12 months. Their average twelve-month price target is $13.25, suggesting that the stock has a possible upside of 216.23%. The high price target for KDMN is $25.00 and the low price target for KDMN is $3.00. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyHoldHoldBuy
Consensus Rating Score: 2.502.402.252.50
Ratings Breakdown: 1 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $13.25$11.40$9.75$9.80
Price Target Upside: 216.23% upside201.59% upside172.35% upside159.95% upside

Kadmon (NYSE:KDMN) Consensus Price Target History

Price Target History for Kadmon (NYSE:KDMN)

Kadmon (NYSE:KDMN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/9/2018HC WainwrightReiterated RatingBuy$25.00HighView Rating Details
2/13/2018Piper JaffrayReiterated RatingOverweight -> Positive$7.00 -> $9.00HighView Rating Details
2/13/2018Jefferies GroupBoost Price TargetPositive -> Buy$16.00HighView Rating Details
10/9/2017WBB SecuritiesDowngradeHold -> Sell$3.00N/AView Rating Details
3/27/2017CitigroupLower Price TargetNeutral$6.00 -> $4.00HighView Rating Details
11/21/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Kadmon (NYSE:KDMN) Earnings History and Estimates Chart

Earnings by Quarter for Kadmon (NYSE:KDMN)

Kadmon (NYSE:KDMN) Earnings Estimates

2018 EPS Consensus Estimate: ($0.94)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.23)($0.23)($0.23)
Q2 20181($0.24)($0.24)($0.24)
Q3 20181($0.23)($0.23)($0.23)
Q4 20181($0.24)($0.24)($0.24)

Kadmon (NYSE KDMN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2018Q4 2017($0.36)($0.24)$3.07 million$1.50 millionViewN/AView Earnings Details
11/9/2017Q3 2017($0.38)($0.42)$5.69 million$2.28 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.49)($0.44)$3.46 million$3.00 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.52)($0.39)$4.25 million$5.60 millionViewN/AView Earnings Details
3/22/2017Q4 2016($0.71)($0.50)$4.50 million$4.28 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.40)($4.23)$3.90 million$5.70 millionViewN/AView Earnings Details
9/7/2016Q2 2016($0.88)($4.42)$6.48 million$6.42 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Kadmon (NYSE:KDMN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Kadmon (NYSE KDMN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.41%
Institutional Ownership Percentage: 61.71%
Insider Trading History for Kadmon (NYSE:KDMN)
Institutional Ownership by Quarter for Kadmon (NYSE:KDMN)

Kadmon (NYSE KDMN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/6/2017Goldentree Asset Management LpMajor ShareholderSell302,950$2.73$827,053.50View SEC Filing  
8/10/2017Harlan WaksalCEOBuy5,000$2.27$11,350.00110,747View SEC Filing  
8/8/2017Eugene BauerDirectorBuy5,000$2.36$11,800.001,716View SEC Filing  
8/8/2017Harlan WaksalCEOBuy3,707$2.34$8,674.38105,747View SEC Filing  
8/8/2017Steven N. GordonVPBuy1,000$2.47$2,470.00View SEC Filing  
7/31/2017Goldentree Asset Management LpMajor ShareholderSell349,661$2.60$909,118.60View SEC Filing  
7/11/2017Goldentree Asset Management LpMajor ShareholderSell34,462$3.69$127,164.78View SEC Filing  
6/29/2017Goldentree Asset Management LpMajor ShareholderSell64,375$4.04$260,075.00View SEC Filing  
6/27/2017Goldentree Asset Management LpMajor ShareholderSell108,827$3.69$401,571.63View SEC Filing  
6/26/2017Goldentree Asset Management LpMajor ShareholderSell515,643$3.51$1,809,906.93View SEC Filing  
6/22/2017Goldentree Asset Management LpMajor ShareholderSell767,363$3.50$2,685,770.50View SEC Filing  
3/13/2017Daniel S LoebMajor ShareholderBuy1,488,095$3.36$4,999,999.20View SEC Filing  
11/16/2016Harlan WaksalCEOBuy2,000$6.37$12,740.00102,040View SEC Filing  
11/14/2016Harlan WaksalCEOBuy2,000$6.79$13,580.00100,040View SEC Filing  
11/11/2016Konstantin PoukalovCFOBuy4,000$5.81$23,240.001,000View SEC Filing  
9/14/2016Daniel S LoebMajor ShareholderBuy19,611$7.79$152,769.69View SEC Filing  
9/13/2016Daniel S LoebMajor ShareholderBuy68,654$8.33$571,887.82View SEC Filing  
9/6/2016Daniel S LoebMajor ShareholderBuy81,781$9.39$767,923.59View SEC Filing  
8/26/2016Daniel S LoebMajor ShareholderBuy32,916$9.98$328,501.68View SEC Filing  
8/22/2016Daniel S LoebMajor ShareholderBuy11,305$10.00$113,050.00View SEC Filing  
8/15/2016Daniel S LoebMajor ShareholderBuy6,010$9.95$59,799.50View SEC Filing  
8/12/2016Daniel S LoebMajor ShareholderBuy87,529$9.98$873,539.42View SEC Filing  
8/5/2016Daniel S LoebMajor ShareholderBuy66,828$9.94$664,270.32View SEC Filing  
8/3/2016Daniel S LoebMajor ShareholderBuy1,431,996$11.35$16,253,154.60View SEC Filing  
8/1/2016Goldentree Asset Management LpMajor ShareholderBuy208,333$12.00$2,499,996.00View SEC Filing  
7/28/2016Bart M SchwartzDirectorBuy2,000$9.77$19,540.0026,211View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Kadmon (NYSE KDMN) News Headlines

Source:
DateHeadline
Kadmon Co. (KDMN) Receives Consensus Recommendation of "Hold" from AnalystsKadmon Co. (KDMN) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 18 at 7:24 PM
ValuEngine Lowers Kadmon (KDMN) to Strong SellValuEngine Lowers Kadmon (KDMN) to Strong Sell
www.americanbankingnews.com - April 14 at 8:35 PM
Piper Jaffray Analysts Give Kadmon (KDMN) a $7.00 Price TargetPiper Jaffray Analysts Give Kadmon (KDMN) a $7.00 Price Target
www.americanbankingnews.com - April 13 at 8:18 PM
Kadmon Receives FDA Guidance on Pivotal Clinical Trial Design for KD025 in Chronic Graft-Versus-Host DiseaseKadmon Receives FDA Guidance on Pivotal Clinical Trial Design for KD025 in Chronic Graft-Versus-Host Disease
finance.yahoo.com - April 10 at 9:56 AM
Kadmon Co. (KDMN) Expected to Post Quarterly Sales of $3.28 MillionKadmon Co. (KDMN) Expected to Post Quarterly Sales of $3.28 Million
www.americanbankingnews.com - April 9 at 3:44 AM
-$0.25 Earnings Per Share Expected for Kadmon Co. (KDMN) This Quarter-$0.25 Earnings Per Share Expected for Kadmon Co. (KDMN) This Quarter
www.americanbankingnews.com - April 7 at 8:09 AM
Kadmon (KDMN) Stock Rating Lowered by Zacks Investment ResearchKadmon (KDMN) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 28 at 3:48 PM
Kadmon Holdings Inc (KDMN) Given Consensus Rating of "Hold" by BrokeragesKadmon Holdings Inc (KDMN) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 24 at 7:33 PM
Kadmon (KDMN) Rating Increased to Hold at Zacks Investment ResearchKadmon (KDMN) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - March 10 at 5:09 PM
Kadmon (KDMN) Earns "Buy" Rating from HC WainwrightKadmon (KDMN) Earns "Buy" Rating from HC Wainwright
www.americanbankingnews.com - March 9 at 10:14 PM
Kadmon Holdings Inc Expected to Earn Q1 2018 Earnings of ($0.23) Per Share (KDMN)Kadmon Holdings Inc Expected to Earn Q1 2018 Earnings of ($0.23) Per Share (KDMN)
www.americanbankingnews.com - March 9 at 7:54 AM
Kadmon Reports Upcoming Milestones and Fourth Quarter and Full ... - Business Wire (press release)Kadmon Reports Upcoming Milestones and Fourth Quarter and Full ... - Business Wire (press release)
www.businesswire.com - March 7 at 5:12 PM
Kadmon (KDMN) Releases  Earnings ResultsKadmon (KDMN) Releases Earnings Results
www.americanbankingnews.com - March 6 at 9:12 PM
Kadmon Reports Upcoming Milestones and Fourth Quarter and Full Year 2017 Financial ResultsKadmon Reports Upcoming Milestones and Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 6 at 4:46 PM
$3.72 Million in Sales Expected for Kadmon Holdings Inc (KDMN) This Quarter$3.72 Million in Sales Expected for Kadmon Holdings Inc (KDMN) This Quarter
www.americanbankingnews.com - March 6 at 8:58 AM
Kadmon Holdings Inc (KDMN) Expected to Post Earnings of -$0.34 Per ShareKadmon Holdings Inc (KDMN) Expected to Post Earnings of -$0.34 Per Share
www.americanbankingnews.com - March 4 at 3:14 AM
Kadmon Holdings Inc (KDMN) Receives Consensus Recommendation of "Hold" from BrokeragesKadmon Holdings Inc (KDMN) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - February 27 at 7:28 PM
Wired News – Kadmon Presented Updated Positive Results from Phase-2 Study of KD025 in Chronic Graft-Versus-Host Disease at BMT Tandem MeetingsWired News – Kadmon Presented Updated Positive Results from Phase-2 Study of KD025 in Chronic Graft-Versus-Host Disease at BMT Tandem Meetings
finance.yahoo.com - February 26 at 9:26 AM
Kadmon (KDMN) Reports Updated Positive Results from Phase 2 Study of KD025 in cGVHD - StreetInsider.comKadmon (KDMN) Reports Updated Positive Results from Phase 2 Study of KD025 in cGVHD - StreetInsider.com
www.streetinsider.com - February 25 at 5:06 PM
Kadmon Announces Updated Positive Results from Phase 2 Study of KD025 in cGVHDKadmon Announces Updated Positive Results from Phase 2 Study of KD025 in cGVHD
finance.yahoo.com - February 23 at 9:27 AM
Kadmon (KDMN) PT Raised to $16.00 at Jefferies GroupKadmon (KDMN) PT Raised to $16.00 at Jefferies Group
www.americanbankingnews.com - February 18 at 8:10 PM
Kadmon Holdings Inc to Post FY2021 Earnings of ($2.83) Per Share, Jefferies Group Forecasts (KDMN)Kadmon Holdings Inc to Post FY2021 Earnings of ($2.83) Per Share, Jefferies Group Forecasts (KDMN)
www.americanbankingnews.com - February 15 at 4:10 PM
-$0.34 EPS Expected for Kadmon Holdings Inc (KDMN) This Quarter-$0.34 EPS Expected for Kadmon Holdings Inc (KDMN) This Quarter
www.americanbankingnews.com - February 15 at 11:10 AM
Kadmon (KDMN) Reports Positive Topline Results from Phase 2 Study of KD025 in Idiopathic Pulmonary FibrosisKadmon (KDMN) Reports Positive Topline Results from Phase 2 Study of KD025 in Idiopathic Pulmonary Fibrosis
www.streetinsider.com - February 14 at 9:07 AM
Why Molina Healthcare, Brighthouse Financial, and Kadmon Holdings Slumped TodayWhy Molina Healthcare, Brighthouse Financial, and Kadmon Holdings Slumped Today
finance.yahoo.com - February 14 at 9:07 AM
Why Karmon's "Positive" Data Turned Into a 21% DeclineWhy Karmon's "Positive" Data Turned Into a 21% Decline
finance.yahoo.com - February 14 at 9:07 AM
Vertex Pharmaceuticals, Kadmon Holdings Are Early Week Biotech MoversVertex Pharmaceuticals, Kadmon Holdings Are Early Week Biotech Movers
finance.yahoo.com - February 13 at 4:28 PM
Kadmon (KDMN) Receives "Positive" Rating from Piper Jaffray CompaniesKadmon (KDMN) Receives "Positive" Rating from Piper Jaffray Companies
www.americanbankingnews.com - February 13 at 11:12 AM
BRIEF-Kadmon Posts Positive Topline Results From Phase 2 Study Of KD025 In Idiopathic Pulmonary FibrosisBRIEF-Kadmon Posts Positive Topline Results From Phase 2 Study Of KD025 In Idiopathic Pulmonary Fibrosis
www.reuters.com - February 13 at 9:05 AM
After-Hours Stock Movers 02/12: (KDMN) (VIPS) (RNG) Higher; (HMNY) (AFMD) (moh) Lower (more...)After-Hours Stock Movers 02/12: (KDMN) (VIPS) (RNG) Higher; (HMNY) (AFMD) (moh) Lower (more...)
www.streetinsider.com - February 13 at 9:05 AM
Kadmon to Host Webcast and Conference Call to Discuss Topline Results of KD025 in IPFKadmon to Host Webcast and Conference Call to Discuss Topline Results of KD025 in IPF
finance.yahoo.com - February 13 at 9:05 AM
Kadmon Announces Positive Topline Results from Phase 2 Study of KD025 in Idiopathic Pulmonary FibrosisKadmon Announces Positive Topline Results from Phase 2 Study of KD025 in Idiopathic Pulmonary Fibrosis
finance.yahoo.com - February 12 at 4:34 PM
Major Biopharma Catalysts on February’s FDA CalendarMajor Biopharma Catalysts on February’s FDA Calendar
247wallst.com - February 3 at 9:01 AM
Kadmon Holdings Inc (KDMN) Receives Average Recommendation of "Hold" from AnalystsKadmon Holdings Inc (KDMN) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - February 2 at 7:22 PM
Kadmon Holdings Inc (KDMN) to Post FY2022 Earnings of ($1.58) Per Share, Jefferies Group ForecastsKadmon Holdings Inc (KDMN) to Post FY2022 Earnings of ($1.58) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - January 29 at 9:10 AM
Kadmon Holdings (KDMN) Jumps: Stock Rises 9.3% - NasdaqKadmon Holdings (KDMN) Jumps: Stock Rises 9.3% - Nasdaq
www.nasdaq.com - January 15 at 4:13 PM
Kadmon Holdings (KDMN) Jumps: Stock Rises 9.3%Kadmon Holdings (KDMN) Jumps: Stock Rises 9.3%
finance.yahoo.com - January 15 at 10:33 AM
Kadmon (KDMN) Lifted to "Buy" at Zacks Investment ResearchKadmon (KDMN) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - January 14 at 8:10 PM
Reviewing Alimera Sciences (ALIM) and Kadmon (KDMN)Reviewing Alimera Sciences (ALIM) and Kadmon (KDMN)
www.americanbankingnews.com - January 14 at 7:34 AM
Kadmon Holdings Inc (KDMN) Expected to Announce Earnings of -$0.34 Per ShareKadmon Holdings Inc (KDMN) Expected to Announce Earnings of -$0.34 Per Share
www.americanbankingnews.com - January 12 at 1:04 PM
Kadmon Holdings Inc (KDMN) Given Consensus Recommendation of "Hold" by BrokeragesKadmon Holdings Inc (KDMN) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 8 at 10:02 PM
KDMN And 10 Other Biotech Stocks You Should Watch This MonthKDMN And 10 Other Biotech Stocks You Should Watch This Month
www.nasdaq.com - January 2 at 4:51 PM
$4.07 Million in Sales Expected for Kadmon Holdings Inc (KDMN) This Quarter$4.07 Million in Sales Expected for Kadmon Holdings Inc (KDMN) This Quarter
www.americanbankingnews.com - December 28 at 2:12 AM
Kadmon Holdings Inc (KDMN) to Post FY2017 Earnings of ($1.73) Per Share, Jefferies Group ForecastsKadmon Holdings Inc (KDMN) to Post FY2017 Earnings of ($1.73) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - December 25 at 2:28 AM
Financial Analysis: Novus Therapeutics (NVUS) & Kadmon (KDMN)Financial Analysis: Novus Therapeutics (NVUS) & Kadmon (KDMN)
www.americanbankingnews.com - December 23 at 3:07 AM
ETFs with exposure to Kadmon Holdings, Inc. : December 20, 2017ETFs with exposure to Kadmon Holdings, Inc. : December 20, 2017
finance.yahoo.com - December 20 at 4:10 PM
Syndax Pharmaceuticals (SNDX) versus Kadmon (KDMN) Financial AnalysisSyndax Pharmaceuticals (SNDX) versus Kadmon (KDMN) Financial Analysis
www.americanbankingnews.com - December 20 at 11:28 AM
Kadmon (KDMN) Stock Rating Reaffirmed by HC WainwrightKadmon (KDMN) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - December 15 at 2:56 PM
Kadmon Holdings, Inc. (KDMN) Given Consensus Rating of "Hold" by BrokeragesKadmon Holdings, Inc. (KDMN) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - December 14 at 11:58 PM
Kadmon (KDMN) & The Competition Head to Head ReviewKadmon (KDMN) & The Competition Head to Head Review
www.americanbankingnews.com - December 14 at 7:16 AM

SEC Filings

Kadmon (NYSE:KDMN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Kadmon (NYSE:KDMN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Kadmon (NYSE KDMN) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.